Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

Novo Nordisk/Eli Lilly’s Weight Loss Drugs Does Not Cause Suicidal Behaviors – After FDA, European Medicines Agency Says

By Vandana Singh
April 12, 10:40 AM
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough reviews and data analyses, no changes to product information were deemed necessary.

AZN

Read More
3 minute read

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement With Mexican Pharmaceutical Manufacturer For Initial Development And Production Of Its Mango Erectile Dysfunction Products

By Benzinga Newsdesk
April 12, 8:46 AM
Signifies the first major step towards the application process for the certification of itsMango ED oral dissolvable products by Mexico's health governing agency, COFEPRISDallas, Texas, April 12, 2024 (GLOBE NEWSWIRE) --

MGRX

Read More
2 minute read

Small-Cap Firm Century Therapeutics’ Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing

By Vandana Singh
April 11, 4:24 PM
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.

IPSC

Read More
2 minute read

Vertex’s Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept’s Potential Impact

By Vandana Singh
April 11, 2:47 PM
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth potential, with Alpine's lead molecule poised to add over $5 billion in sales.

ALPN

Read More
1 minute read

Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?

By Vandana Singh
April 11, 12:13 PM
Janux Therapeutics may be up for sale amid interest from major pharmaceutical firms. With shares quadrupling this year and a successful equity offering, Janux is making waves in the industry. The pharmaceutical industry has seen a surge in deal activities, with acquisitions totaling $27.8 billion since the year's start.

JANX